YMTX's Business Model
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.yumanity.com |
CEO (Chief Executive Officer) | |
Number of Employees | |
IPO date | February 11, 2016 |
YMTX Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 40 Guest Street |
City | Boston |
State | MA |
Phone | 617 409 5300 |
Zip Code | 02135 |
Other Identifiers | |
CIK | 0001445283 |
ISIN | US98872L1026 |
CUSIP | 98872L102 |
Open | 1.63 |
Previous Close | 1.74 |
Volume | 697.5 Thou. |
Average Volume | 132.4 Thou. |
Day’s Range | 1.4 – 1.89 |
52 Week Range | 0.95-3.37 |
MA (50) | 1.767714 |
MA (200) | 1.585122 |
Market Cap | 15.72 Mil. |
Shares Out. | 8.32 Mil. |
Earnings Date | |
Beta | |
Last Dividend | |
EPS | |
PE | |